Symbio Announces Phase I Clinical Unit
Symbio LLC, a full service contract research organization, has announced the opening of a new Phase I Clinical Unit in Michigan City, Indiana.
Port Jefferson, NY – Symbio LLC, a full service contract research organization, has announced the opening of a new Phase I Clinical Unit. Since 2002, Symbio has provided services to pharmaceutical, generic and medical device companies that have resulted in many successful clinical trials. Services provided by Symbio include: clinical trial management, biometrics, strategic consulting, product development and topical formulation development. With the addition of the Phase I Unit, a key component to the complete clinical development process, Symbio now has the ability to provide development from Phase I through Phase IV.
In collaboration with Saint Anthony Memorial Hospital in Michigan City, Indiana, the Phase I Unit is a 62 bed capacity facility and is located within the confines of Saint Anthony Memorial Hospital. The hospital provides an entire floor devoted to the conduct of Phase I studies, ensuring the highest quality medical care and safety standards.
Symbio has long-standing, special expertise working with the generic drug industry. The Symbio Phase I Clinical Team is set up to prepare and execute clinical plans to support FDA approval of generic products.
Symbio’s Phase I Unit at Saint Anthony Memorial Hospital is centrally located in northwest Indiana, between the Illinois and Michigan state borders.
Just 45 minutes from downtown Chicago, diverse populations of healthy participants are easily accessible including eight local colleges/universities and technical schools.
For further information contact: Edward Drower, Director of Phase I Clinical Operations
Phone: 219-861-8817, Email: edrower@symbioresearch.com
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
